Food Allergies

A Phase 1, open label trial demonstrated the safety of Fecal Microbiota Transplants in peanut allergic patients. 30% of patients increased their amount of peanut protein they consumed without reaction.

A secondary phase 1, open label clinical trial was completed, including an antibiotic treatment prior to the administration of FMT. In this trial, 60% patients improved their peanut protein reactivity after one FMT. Additional information about this trial is available here.

A new, phase 2, randomized, double-blind, placebo-controlled clinical trial is underway to investigate the impact of higher dosing of microbiota transplant therapy in patients with peanut allergies. In this trial, patients will receive a pre-antibiotic followed by 27 days of microbiota transplant therapy capsules or placebo capsules. Read more about the clinical trial here.